Skip to main content

Table 1 Patient and tumor characteristics and comparisons of patient groups

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Characteristic All patients
N (%)
CMF-treated patients
N (%)
Anthracycline-treated patients
N (%)
Untreated patients
N (%)
P1
Age      
≤ 40 years 164 (31) 110 (34) 28 (28) 26 (25) 0.212
41-55 years 361 (69) 214 (66) 71 (72) 76 (75)  
Involved lymph nodes      
1-3 292 (56) 217 (67) 47 (47) 28 (27) <0.0012
>3 233 (44) 107 (33) 52 (53) 74 (73)  
Steroid hormone rec. status      
Positive 432 (82) 269 (83) 76 (77) 87 (85) 0.242
Negative 93 (18) 55 (17) 23 (23) 15 (15)  
Tumor size      
pT1 175 (33) 131 (40) 21 (21) 23 (23) <0.0012
pT2 270 (51) 147 (45) 58 (59) 65 (64)  
pT3+4 80 (15) 46 (14) 20 (20) 14 (14)  
Grade      
Well/moderate 103 (20) 65 (20) 21 (21) 17 (17) 0.332
Poor 291 (55) 174 (54) 61 (62) 56 (55)  
Unknown 131 (25) 85 (26) 17 (17) 29 (28)  
Primary treatment      
Lumpectomy 212 (40) 169 (52) 4 (4) 39 (38) <0.0012
Mastectomy 313 (60) 155 (48) 95 (96) 63 (62)  
Events 3      
Recurrences (disease failure) 268 140 58 70  
Deaths 149 75 32 42  
TIMP-1 (median, range) 12.5 (0- 113) 12.0 (0- 106) 13.5 (0-51.2) 13.8 (0- 113) 0.204
  1. All patients, N = 525; CMF-treated patients, N = 324; anthracycline-treated, N = 99; untreated patients, N = 102.
  2. 1Testing the hypothesis that subgroups (CMF- or anthracycline treated and untreated) are similar
  3. 2Pearson X2 test
  4. 3Events when censored at 60 months
  5. 4Kruskal-Wallis equality-of-populations rank test